1 / 14

HIV Prophylaxis: Following Occupational and Non-Occupational Exposure

HIV Prophylaxis: Following Occupational and Non-Occupational Exposure. Nanik ( Nayri ) Hatsakorzian Pharm.D ./MPH candidate 2014 Touro University, College of Pharmacy-CA. Quiz. Patient: Jane Do DOB: 09/09/59 Truvada Take 1 tab PO QD # 30 Refill: 6 Doctor: Homer Simpson

morse
Download Presentation

HIV Prophylaxis: Following Occupational and Non-Occupational Exposure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. HIV Prophylaxis: Following Occupational and Non-Occupational Exposure Nanik (Nayri) Hatsakorzian Pharm.D./MPH candidate 2014 Touro University, College of Pharmacy-CA

  2. Quiz Patient: Jane Do DOB: 09/09/59 Truvada Take 1 tab PO QD # 30 Refill: 6 Doctor: Homer Simpson DEA: J000999000 (415)555-5555

  3. What do you do? • A- call the MD office and ask about the rest of the regimen • B- call the MD office and demand an explanation for the refill number • C- assume it is for Hep B treatment, so consult the patient accordingly • D- Just fill as is, and consult the patient on adherence and possible side effects of the drug • E- have an open communication with the patient during the consultation • F- Shrug your shoulder and say “This crazy doctor sends weird rx all the time”

  4. PEP: For Occupational Exposure

  5. Preferred Regimens and duration • Truvada (TDF: 300 mg and FTC: 200 mg) • 1 tab QD for 4 weeks • Combivir (ZDV: 300 mg and 3TC: 300 mg) • 1 tab BID for 4 weeks • Other preferred regimens include: • ZDV: 300 mg BID and Emtricitabine 200 mg QD • TDF: 300 mg QD and Lamivudine 300mg QD (or 150 mg BID)

  6. Preferred Expanded Regimen • Basic regimen plus: • Kaletra 400/100 mg BID Alternative Expanded Regimen • Basic regimen plus: • Atazanavir (400 or 300 mg) +/- ritonavir OD • Efavirenz 600 mg QD (Combo with Truvada= Atripla)

  7. PEP: Non-Occupational Exposure

  8. Preferred Regimens and Duration • Atripla (TDF/FTC/EFV) for 4 weeks • or Efavirenz with lamivudine and zidovudine Alternative Regimens and Duration • Atazanavir +lamivudine or emtricitabine + zidovudineor stavudine or abacavir or didanosine or tenofovir (boosted with TDF)

  9. Pre-Exposure Prophylaxis (PrEP) • On January 2011 and August 2012, FDA approved Truvada once a day as pre-exposure prophylaxis for HIV prevention in MSM and among heterosexual serodiscordant couples and high risk HIV negative couples, respectively. • CDC recommends clinicians to provide 90 days supply when initiating PreP, and renewable only after HIV negative test results. • There has been no adverse effects in infants exposed to Truvada. However, couples using Truvada during attempts to conceive should be warned of possible adverse events.

  10. iPrEX Study • FDA has approved Truvada once a day as PrEP upon results from iPrEXstudy • A multinational, randomized, double-blind, placebo-controlled, phase III clinical trial of daily oral Truvada to prevent acquisition of HIV infection among uninfected but exposed MSM  • iPrEX concluded that once-daily oral FTC–TDF provided a 44% additional protection from HIV among men or transgender women who have sex with men who also received a comprehensive package of prevention services. • iPrEX also concluded poor adherence with higher risk of infection.

  11. Further studies • TDF2 • Phase III, randomized, double-blind, placebo-controlled clinical trial • TDF/FTC once daily, decreased the rate of HIV infection in heterosexual men by 62.2% when it was administered as part of a comprehensive package of HIV-prevention services. • FEM-PrEP • Randomized, double-blind, placebo-controlled trial with the primary objective of assessing effectiveness of TDF–FTC in preventing HIV acquisition and evaluate safety. • The study was stopped early due to lack of efficacy • Good example of failure due to lack of adherence • CDC 4370 (Bangkok TDF study) • Phase III, randomized, double-blind, placebo-controlled, HIV pre-exposure prophylaxis trial of daily oral tenofovir. • Trial results will demonstrate whether or not daily oral tenofovir reduces the risk of HIV infection among IDUs

  12. Answer • This prescription is written as PrEX. Pharmacist has to consult accordingly with emphasis on the importance of the adherence

  13. As pharmacists • It is very important to differentiate types of HIV prescriptions received at the pharmacy. Misunderstanding the purpose of a drug regimen can lead to several complications including: • Unnecessary phone calls to MD office • Unnecessary wait for patient • Confusion caused to the patient by questioning the prescription and prescriber competency • Wrong and incomplete consultation • Disturbance in communication circle between provider, patient, and pharmacist • It is also important to recognize the purpose of the prescription since it alters the content of the consultation. Adherence is a vital part of consultation when it comes to HIV drugs, but it gains extra importance during PEP and PrEP consultations.

  14. References • CDC. MMWR. Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States. Recommendations from the U.S. Department of Health and Human Services. 2005. Retrieved from http://aidsinfo.nih.gov/contentfiles/NonOccupationalExposureGL.pdf • CDC. MMWR. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for PostexposureProphylaxis. 2005. Retrieved fromhttp://aidsinfo.nih.gov/contentfiles/HealthCareOccupExpoGL.pdf • CDC. MMWR. Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. 2011. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm • CDC. MMWR. Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults. 2012. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a2.htm?s_cid=mm6131a2_w#tab2

More Related